Drug Trial Radar · NCT04941599
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Feb 14, 2024
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Vanderbilt University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Jun 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.
Conditions
- Familial Hypercholesterolemia
Interventions
2-HydroxybenzylamineDrug
2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
PlaceboOther
Placebo 250 mg three tabs TID (po) for 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 2-HOBA increases HDL cholesterol efflux capacity.Time frame: Baseline to week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.